8-K: Biomerica Announces $5.5 Million At-the-Market Offering and Nasdaq Non-Compliance Notice

Biomerica has entered into an agreement to sell up to $5.5 million of its common stock through an at-the-market offering and received a notice from Nasdaq regarding non-compliance with minimum bid price requirements.

Summary

• Biomerica, Inc. has entered into an At Market Issuance Sales Agreement with EF Hutton LLC and R.F. Lafferty & Co., Inc. to sell up to $5.5 million of its common stock.
• The company will pay the sales agents a commission of 2.0% of the gross sale price per share.
• Biomerica intends to use the net proceeds for general corporate purposes, including sales and marketing, clinical studies, product development, acquisitions, capital expenditures, and working capital.
• The company received a notice from Nasdaq stating that its stock price has been below $1.00 for 32 consecutive business days, putting it out of compliance with Nasdaq listing rules.
• Biomerica has 180 calendar days, until November 4, 2024, to regain compliance by having its stock price close at or above $1.00 for a minimum of ten consecutive business days.
• If the company fails to regain compliance, Nasdaq may grant an additional compliance period if certain conditions are met, otherwise the stock may be delisted.

Sentiment

Score: 4

Explanation: The document contains both positive and negative elements. The capital raise is positive, but the Nasdaq non-compliance notice is a significant negative. The overall sentiment is slightly negative due to the delisting risk.

Positives

• The at-the-market offering provides Biomerica with a flexible way to raise capital.
• The company has a clear plan for the use of proceeds, including growth initiatives and potential acquisitions.
• Biomerica has a period of 180 days to regain compliance with Nasdaq listing rules, which provides an opportunity to improve its stock price.

Negatives

• The company's stock price has fallen below $1.00, resulting in a non-compliance notice from Nasdaq.
• There is no guarantee that the company will be able to regain compliance with Nasdaq listing rules.
• The company will incur a 2.0% commission on the gross sale price of each share sold, reducing the net proceeds from the offering.

Risks

• There is a risk that Biomerica will not be able to regain compliance with Nasdaq listing rules, which could lead to delisting.
• The at-the-market offering could dilute existing shareholders if a large number of shares are sold.
• There is no guarantee that the company will be able to successfully execute its plans for the use of proceeds.
• The company's stock price may continue to decline, making it more difficult to raise capital in the future.

Future Outlook

Biomerica intends to use the net proceeds from the offering for general corporate purposes, including sales and marketing, clinical studies, product development, acquisitions, capital expenditures, and working capital. The company will actively monitor its stock price and consider options to regain compliance with Nasdaq listing rules.

Management Comments

• The company intends to actively monitor the minimum bid price of its common stock and may, as appropriate, consider available options to regain compliance with the Rule.

Industry Context

At-the-market offerings are a common method for companies to raise capital, particularly when they need flexibility in timing and pricing. The Nasdaq non-compliance notice highlights the challenges faced by companies with declining stock prices, which can impact their ability to raise capital and maintain their listing status.

Comparison to Industry Standards

• At-the-market offerings are a common practice for companies seeking flexible capital raising options, similar to other small-cap and micro-cap companies in the biotech and healthcare sectors.
• The 2% commission is within the typical range for such offerings, although it can vary based on the size and complexity of the deal.
• The 180-day compliance period is standard for Nasdaq non-compliance notices, and many companies in similar situations have successfully regained compliance.
• Companies like Agenus Inc. and Veru Inc. have also faced similar delisting risks and have taken steps to regain compliance, including reverse stock splits and other measures.

Stakeholder Impact

• Shareholders face the risk of further stock dilution from the at-the-market offering.
• Shareholders also face the risk of delisting if the company fails to regain compliance with Nasdaq listing rules.
• Employees may be impacted by the company's financial performance and potential restructuring.
• Customers and suppliers may be impacted by the company's ability to continue operations and invest in product development.

Next Steps

• Biomerica will actively monitor its stock price to regain compliance with Nasdaq listing rules.
• The company will proceed with the at-the-market offering to raise capital.
• Biomerica may consider other options to regain compliance, such as a reverse stock split.

Key Dates

Keywords

at-the-market offering, common stock, Nasdaq, non-compliance, minimum bid price, capital raise, sales agreement, delisting, compliance period, EF Hutton, R.F. Lafferty